BeiGene, Ltd. (ONC)

Market Cap	28.75B
Revenue (ttm)	3.81B
Net Income (ttm)	-644.79M
Shares Out	107.54M
EPS (ttm)	-6.12
PE Ratio	n/a
Forward PE	184.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	490,044
Open	269.00
Previous Close	262.60
Day's Range	265.49 - 274.02
52-Week Range	126.97 - 287.88
Beta	0.65
Analysts	Buy
Price Target	330.50 (+23.6%)
Earnings Date	May 7, 2025

About ONC

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://www.beigene.com

Financial Performance

In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for ONC stock is "Buy." The 12-month stock price forecast is $330.5, which is an increase of 23.60% from the latest price.

Price Target

$330.5

(23.60% upside)

Analyst Consensus: Buy